Telix Pharmaceuticals (TLX) Long-Term Investments (2024 - 2026)

Telix Pharmaceuticals (TLX) has reported Long-Term Investments for 3 consecutive years, with $37.1 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Long-Term Investments rose 1.12% year-over-year to $37.1 million; the TTM figure through Dec 2025 stood at $37.1 million (up 1.12% YoY), while the FY2025 annual figure was $37.1 million, up 6.76% from the prior year.
• Long-Term Investments advanced to $37.1 million in Q4 2025 per TLX's latest filing, from $36.7 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $37.1 million in Q4 2025 and bottomed at $8.0 million in Q4 2023.
• Historically, Long-Term Investments has averaged $27.3 million across 3 years, with a median of $36.7 million in 2024.
• Annual changes were most pronounced in 2024 — Long-Term Investments surged 359.61% — and 2025, when it gained 1.12%.
• Telix Pharmaceuticals' Long-Term Investments stood at $8.0 million in 2023, then soared by 359.61% to $36.7 million in 2024, then climbed by 1.12% to $37.1 million in 2025.
• Business Quant data shows TLX's Long-Term Investments at $37.1 million in Q4 2025, $36.7 million in Q4 2024, and $8.0 million in Q4 2023.